IC
CMPX icon

Ikarian Capital’s Compass Therapeutics CMPX Stock Holding History

Ikarian Capital’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4K Hold
18,000
– – ﹤0.01% 151
2026
Q1 		$95.2K Sell
18,000
-782,000
-98% -$4.51M 0.01% 149
2025
Q4 		$4.3M Buy
+800,000
New +$3.69M 0.34% 68
2022
Q2 		– Sell
-74,171
Closed -$100K – 156
2022
Q1 		$100K Buy
74,171
+4,171
+6% +$8.62K 0.01% 181
2021
Q4 		$222K Buy
+70,000
New +$232K 0.03% 154

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ikarian Capital's CMPX Position: Q2 2026 in Review

Ikarian Capital held its Compass Therapeutics (CMPX) position steady in Q2 2026 at 18,000 shares worth $39.4K. The position accounts for ﹤0.01% of the portfolio, ranked #151.

Ikarian Capital first reported a position in CMPX in Q4 2021 and has held it in 5 quarters since. The position peaked at $4.3M in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Ikarian Capital held 18,000 shares of Compass Therapeutics worth $39.4K as of Q2 2026.
  • Ikarian Capital left its Compass Therapeutics share count unchanged in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Ikarian Capital's portfolio in Q2 2026, its #151 holding.
  • Ikarian Capital first reported a position in Compass Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • Ikarian Capital's Compass Therapeutics position peaked at $4.3M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.